查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095093

糖尿病相關眼科治療市場：全球預測，2026-2032年

Diabetes Associated Ophthalmic Treatment Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，糖尿病相關眼科治療市場將成長至 554.2 億美元，複合年成長率為 7.24%。

主要市場統計數據
基準年 2025 339.5億美元
預計年份：2026年 363.4億美元
預測年份 2032 554.2億美元
複合年成長率 (%) 7.24%

糖尿病相關眼科護理包括糖尿病視網膜病變、糖尿病性黃斑部水腫、白內障風險、青光眼風險以及其他糖尿病相關致盲併發症的篩檢、診斷、監測和管理。臨床需求龐大。根據國際糖尿病聯盟（IDF）統計，全球數億成年人患有糖尿病，世界衛生組織（WHO）將糖尿病視網膜病變列為工作年齡成年人可預防性視力障礙的主要原因之一。隨著人口老化、都市化加快以及病程延長，糖尿病盛行率不斷上升，因此，早期眼科檢查、視網膜成像、玻璃體內注射抗血管內皮生長因子（VEGF）治療、皮質類固醇植入、雷射光凝、玻璃體切除手術術以及連接內分泌科、基層醫療、驗光科和眼科的綜合護理路徑的需求日益成長。

整體情況受實證指引的影響，這些指引建議對糖尿病患者進行定期散瞳眼底檢查和檢驗的視網膜照相，治療強度取決於視網膜病變的嚴重程度和黃斑受累範圍。在許多臨床環境中，抗VEGF注射仍是治療中心性糖尿病黃斑部水腫和增殖性糖尿病視網膜病變的核心手段，其療效已得到隨機臨床試驗的支持，證實可顯著改善視力。同時，雷射治療、手術和抗發炎療法對某些患者仍然至關重要，尤其是在藥物依從性、醫療服務可近性或禁忌症影響治療決策的情況下。對於眼科、糖尿病照護、診斷和醫療保健系統的相關人員，工作重點正從臨時治療轉向長期疾病管理、早期發現和預防可預防性失明。

糖尿病眼科護理格局的變革性變化

在糖尿病眼科領域，一場結構性轉變正在發生，從晚期干預轉向以技術驅動的預防性視網膜護理。篩檢模式擴大採用數位眼底照相、光學同調斷層掃描（OCT）、遠距眼科會診和風險分層轉診途徑，以便在發生不可逆視力喪失之前識別糖尿病視網膜病變。這項轉變與公共衛生建議一致，這些建議強調早期發現、血糖控制、血壓管理、血脂最佳化和及時眼科治療，以延緩病情進展。

人工智慧對糖尿病眼科疾病治療的累積影響

人工智慧正透過提高篩檢的擴充性、分診的一致性、工作流程的效率以及決策支援能力，對糖尿病眼科疾病的整體診療產生累積影響。同行評審的研究和監管審查表明，在指定環境下，自主或輔助人工智慧系統能夠以具有臨床意義的靈敏度和特異性，從視網膜影像中檢測出輕度至重度的糖尿病視網膜病變。這一點尤其重要，因為許多醣尿病患者未能接受建議的年度或兩年一次的眼科檢查，而且在農村和資源匱乏地區，專科醫生的短缺仍然是一大障礙。

亞太地區、北美地區、拉丁美洲地區、歐洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區面臨著全球最沉重的糖尿病負擔之一，這主要是由於中國和印度的患者數量龐大，以及日本、韓國和澳洲等國人口老化速度加快。這給糖尿病視網膜病變篩檢和眼科轉診系統帶來了巨大壓力。儘管該地區的都市區醫院擴大採用視網膜成像、光學同調斷層掃描（OCT）、玻璃體內注射治療和玻璃體視網膜手術等綜合方法，但公共衛生計畫正在擴大遠距眼科和社區篩檢的範圍，以彌合大都會圈和農村地區之間的醫療保健差距。

東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團分析

在東南亞國協，隨著都市區和半都市區糖尿病盛行率的上升，糖尿病視網膜擴充性的篩檢已成為優先事項。儘管東協各國的醫療保健系統越來越依賴與初級保健、轉診流程和公立醫院眼科網路相結合的視網膜攝影，但高所得國家和資源匱乏的成員國在醫療保健服務取得方面仍存在顯著差異。海灣合作理事會（GCC）是糖尿病相關眼科需求最為迫切的地區之一，因為其代謝性疾病盛行率很高。海灣合作理事會的醫療保健系統正在推動專業的視網膜護理服務、數位篩檢以及以改善生活方式和早期診斷為重點的預防宣傳活動。

主要糖尿病相關眼科治療市場的關鍵國家特定洞察

在美國，視網膜治療體系已相當完善，玻璃體內注射抗VEGF療法應用廣泛，人工智慧輔助的糖尿病視網膜病變篩檢也不斷普及。然而，不同社會經濟和地域群體參與建議眼科檢查的比例仍有差異。在加拿大，政府重視以指引為基礎的糖尿病眼科疾病篩檢和公共支持的診療路徑，並持續致力於確保偏遠地區和原住民社區的醫療服務可近性。墨西哥和巴西面臨沉重的糖尿病負擔，儘管兩國正在努力擴大篩檢和眼科醫療保健體系，但診斷延誤、自付費用以及地區差異等問題仍影響著治療效果。

為行業領導者提供的實用建議

產業領導者應優先考慮整合糖尿病眼科診療模式，將糖尿病管理、視網膜篩檢、診斷、治療和追蹤整合到單一的患者照護路徑中。投資應重點關注可互通的成像平台、人工智慧輔助的分流系統、光學同調斷層掃描（OCT）的普及以及能夠縮短從篩檢異常到視網膜專科醫生評估時間的轉診系統。產品和服務策略應透過支持長期照護、藥物依從性計畫、病患導航和靈活的就醫環境，來減輕實際診療中的治療負擔。

調查方法

本執行摘要基於系統的二手研究途徑，參考了檢驗的臨床、監管和公共衛生資訊來源。證據來源包括關於糖尿病和眼部健康的國際出版物、眼科學會指南、同行評審的臨床試驗文獻、衛生部門建議、疾病負擔報告以及已記錄的篩檢計畫結果。本分析重點在於糖尿病視網膜病變和糖尿病黃斑部水腫的臨床有效治療方法，包括抗血管內皮生長因子（VEGF）療法、皮質類固醇療法、雷射光凝術、玻璃體玻璃體切除手術、光學同調斷層掃描（OCT）、遠距眼科和人工智慧輔助篩檢。

結論

糖尿病相關眼科治療正朝著以預防主導、以數位化為驅動的多學科領域發展。糖尿病盛行率的上升、預期壽命的延長以及持續存在的篩檢差異凸顯了早期視網膜評估和及時干預的重要性。實證療法，特別是針對糖尿病性黃斑部水腫和增殖性糖尿病視網膜病變的抗VEGF療法，正在改善患者的視覺功能預後，而雷射、皮質類固醇和手術治療在某些情況下仍然必不可少。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 糖尿病相關眼科治療市場：依產品類型分類

  • 製藥
    • 生物製劑
    • 低分子化合物
  • 裝置
    • 診斷設備
    • 外科器械
    • 雷射系統

第8章：糖尿病相關眼科治療市場：依治療類型分類

  • 抗 VEGF
    • 阿柏西普
    • Bevacizumab
    • 布羅盧西珠單抗
    • 法利西單抗
    • 雷尼珠單抗
  • 皮質類固醇
    • 地塞米松植入式劑
    • 氟植入式植入劑
    • 曲安奈德
  • 雷射治療
    • 局部/網格狀光凝療法
    • 全視網膜光凝固術
  • 手術介入

第9章：糖尿病相關眼科治療市場：依給藥途徑分類

  • 玻璃體內注射
    • 預填充式注射器
    • 管瓶
  • 全身
    • 靜脈
    • 口服
  • 外用
    • 眼藥水
    • 軟膏

第10章：糖尿病相關眼科治療市場：依患者類型分類

  • 1型糖尿病
  • 2型糖尿病

第11章：糖尿病相關眼科治療市場：依最終使用者分類

  • 門診手術中心
  • 醫院
  • 眼科診所
  • 零售藥房

第12章：糖尿病相關眼科治療市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章：糖尿病相關眼科治療市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 糖尿病相關眼科治療市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adverum Biotechnologies, Inc.
  • Alcon Vision LLC
  • Alimera Sciences, Inc.
  • Allergan PLC
  • Amgen Inc
  • Ampio Pharmaceuticals, Inc.
  • ANI Pharmaceuticals, Inc.
  • Apexian Pharmaceuticals, Inc.
  • Bausch & Lomb Incorporated.
  • Bayer AG
  • Biocon Limited
  • Biogen Inc.
  • Carl Zeiss Meditec AG
  • Eisai Co Ltd.
  • F. Hoffmann-La Roche Ltd
  • IRIDEX Corp.
  • Johnson & Johnson Services, Inc.
  • Kalvista Pharmaceuticals Ltd.
  • Kodiak Sciences Inc.
  • Kubota Vision Inc.
  • Lumenis
  • Novartis AG
  • Ocuphire Pharma, Inc.
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc.
  • Samsung Biologics Co., Ltd.
  • Sandoz Group AG
  • Santen Pharmaceutical Co. Ltd.
  • Topcon Corp.
Product Code: MRR-563BF1FCF469

The Diabetes Associated Ophthalmic Treatment Market is projected to grow by USD 55.42 billion at a CAGR of 7.24% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 33.95 billion
Estimated Year [2026] USD 36.34 billion
Forecast Year [2032] USD 55.42 billion
CAGR (%) 7.24%

Diabetes associated ophthalmic treatment encompasses the screening, diagnosis, monitoring, and management of diabetic retinopathy, diabetic macular edema, cataract risk, glaucoma risk, and other vision-threatening complications linked to diabetes. The clinical need is substantial: the International Diabetes Federation reports that hundreds of millions of adults live with diabetes worldwide, while the World Health Organization identifies diabetic retinopathy as a leading cause of preventable vision impairment among working-age adults. As diabetes prevalence rises alongside population aging, urbanization, and longer disease duration, demand is intensifying for earlier eye examinations, retinal imaging, intravitreal anti-VEGF therapy, corticosteroid implants, laser photocoagulation, vitrectomy, and integrated care pathways that connect endocrinology, primary care, optometry, and ophthalmology.

The treatment landscape is shaped by evidence-based guidelines recommending routine dilated eye examinations or validated retinal photography for people with diabetes, with treatment intensity determined by retinopathy severity and macular involvement. Anti-VEGF injections remain central for center-involving diabetic macular edema and proliferative diabetic retinopathy in many care settings, supported by randomized clinical trials demonstrating meaningful visual outcomes. At the same time, laser therapy, surgery, and inflammation-targeted options remain important for selected patients, particularly where adherence, access, or contraindications affect treatment decisions. For stakeholders across ophthalmology, diabetes care, diagnostics, and health systems, the priority is shifting from episodic treatment toward longitudinal disease control, earlier detection, and prevention of avoidable blindness.

Transformative Shifts in the Diabetes Eye Care Landscape

The diabetes associated ophthalmic treatment landscape is undergoing a structural shift from late-stage intervention to proactive, technology-enabled retinal care. Screening models increasingly use digital fundus photography, optical coherence tomography, teleophthalmology, and risk-stratified referral pathways to identify diabetic retinopathy before irreversible vision loss occurs. This transition aligns with public health recommendations emphasizing early detection, glycemic control, blood pressure management, lipid optimization, and timely ophthalmic treatment to reduce progression.

Therapeutically, the field is moving toward individualized regimens that balance efficacy, treatment burden, safety, and real-world adherence. Anti-VEGF therapy has transformed the management of diabetic macular edema and proliferative diabetic retinopathy, but frequent injections, missed visits, and unequal access continue to affect outcomes. Longer-acting intravitreal therapies, sustained-release corticosteroid approaches, refined laser protocols, and surgical advances are being integrated based on patient phenotype, ocular comorbidities, pregnancy status, renal disease, cardiovascular risk, and ability to attend follow-up visits. Care delivery is also changing through multidisciplinary diabetes eye programs, community-based screening, mobile imaging units, and referral networks designed to reach underserved populations. These shifts are making the sector less procedure-centric and more prevention-oriented, outcomes-driven, and digitally connected.

Cumulative Impact of Artificial Intelligence on Diabetic Eye Treatment

Artificial intelligence is having a cumulative impact across diabetic eye disease care by improving screening scalability, triage consistency, workflow efficiency, and decision support. Peer-reviewed studies and regulatory reviews have shown that autonomous or assistive AI systems can detect more-than-mild diabetic retinopathy from retinal images with clinically relevant sensitivity and specificity when used in defined settings. This is particularly important because many people with diabetes do not receive recommended annual or biennial eye examinations, and specialist shortages remain a barrier in rural and low-resource settings.

AI-enabled retinal screening supports earlier identification of referable diabetic retinopathy, reduces avoidable specialist appointments for low-risk cases, and helps prioritize patients needing urgent ophthalmic evaluation. When combined with optical coherence tomography, electronic health records, and diabetes registries, AI can support risk stratification for progression, adherence monitoring, and population health management. However, its impact depends on image quality, representative training datasets, validation across ethnic groups, integration with clinical workflows, cybersecurity safeguards, transparent performance monitoring, and clear escalation pathways. The most effective deployment models use AI as part of a governed care continuum rather than as a standalone technology, ensuring that positive findings translate into confirmatory diagnosis, timely treatment, and documented follow-up.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific carries one of the world's largest diabetes burdens, led by high absolute patient populations in China and India and rapidly aging societies such as Japan, South Korea, and Australia. This creates substantial pressure on diabetic retinopathy screening capacity and ophthalmology referral systems. Urban hospitals in the region increasingly combine retinal imaging, optical coherence tomography, intravitreal therapy, and vitreoretinal surgery, while public health programs are expanding teleophthalmology and community screening to address gaps between metropolitan and rural care.

North America benefits from established clinical guidelines, broad use of anti-VEGF therapy, advanced imaging infrastructure, and growing adoption of AI-assisted retinal screening in primary care and diabetes clinics. The United States and Canada emphasize quality metrics, diabetic eye exam adherence, and integrated electronic health records, although disparities persist by insurance status, income, geography, and ethnicity. Latin America faces rising diabetes prevalence with uneven access to retina specialists and imaging technology; countries such as Brazil and Mexico are strengthening public ophthalmology services, but delayed diagnosis and fragmented referral pathways remain key barriers. Europe is characterized by strong screening traditions, particularly in countries with organized national or regional diabetic eye programs, alongside broad adoption of evidence-based treatment guidelines and reimbursement frameworks that support intravitreal therapy.

The Middle East is experiencing high diabetes prevalence linked to lifestyle transitions, obesity, and metabolic risk factors, making diabetic eye disease an important health system priority. GCC countries are investing in specialty eye centers, digital health, and prevention initiatives, while non-GCC settings show more variable access to advanced treatment. Africa faces the greatest challenge in screening coverage, specialist availability, and affordability of advanced retinal care. Nonetheless, mobile fundus photography, task-shifting, teleophthalmology, and international public health collaborations are improving early detection potential in settings where preventable vision loss remains a major concern.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are prioritizing scalable diabetic retinopathy screening as diabetes prevalence rises across urban and semi-urban populations. Health systems in this group increasingly rely on primary-care-linked retinal photography, referral protocols, and public hospital ophthalmology networks, although access varies widely between high-income and lower-resource member states. The GCC has one of the most urgent diabetes-related ophthalmic care needs due to high metabolic disease prevalence, and its health systems are advancing specialty retina services, digital screening, and prevention campaigns focused on lifestyle modification and early diagnosis.

The European Union benefits from structured health technology assessment, cross-border clinical guidance, and organized screening models in several member states. EU priorities include reducing preventable blindness, ensuring equitable access to intravitreal therapies, and improving real-world adherence to diabetic eye examinations. BRICS countries represent a large and diverse diabetic eye care burden, combining advanced tertiary retina centers with significant rural and affordability gaps. China, India, Brazil, Russia, and South Africa each face distinct implementation challenges, but all share the need for high-throughput screening, trained retinal specialists, and treatment pathways that reduce late-stage presentation.

G7 countries generally have mature ophthalmic care infrastructure, advanced imaging access, and strong clinical research ecosystems, supporting rapid translation of evidence-based treatments into practice. However, even within G7 health systems, missed screening appointments and unequal access among marginalized populations remain persistent issues. NATO member countries overlap substantially with high-income North American and European systems, where diabetic eye disease management increasingly intersects with military health readiness, veteran care, digital health security, and resilient medical supply chains for ophthalmic drugs, imaging devices, and surgical consumables.

Key Country Insights Across Major Diabetes Associated Ophthalmic Treatment Markets

The United States has advanced retina treatment capacity, extensive use of intravitreal anti-VEGF therapy, and growing implementation of AI-based diabetic retinopathy screening, yet adherence to recommended eye exams remains uneven across socioeconomic and geographic groups. Canada emphasizes guideline-driven diabetic eye screening and publicly supported care pathways, with continued attention to remote and Indigenous community access. Mexico and Brazil face high diabetes burdens and are expanding screening and ophthalmology capacity, but delayed diagnosis, out-of-pocket costs, and regional disparities continue to influence treatment outcomes.

In Europe, the United Kingdom is recognized for organized diabetic eye screening, which has contributed to earlier detection and reduced preventable blindness among working-age adults. Germany, France, Italy, and Spain combine specialist retina networks, optical coherence tomography use, and evidence-based intravitreal therapy with differing reimbursement and regional access structures. Russia has a significant diabetes care burden across a broad geography, making telemedicine, regional referral coordination, and imaging availability important for diabetic eye disease management.

China and India account for very large populations living with diabetes, making diabetic retinopathy screening scale a central public health issue. China is strengthening hospital-based retina services and digital screening capabilities, while India has extensive ophthalmology expertise and outreach models but continues to face rural access and affordability challenges. Japan, South Korea, and Australia have advanced imaging and treatment infrastructure, high clinical guideline adoption, and growing emphasis on aging-related eye disease comorbidity. Australia's care model also highlights the importance of reaching remote communities through teleophthalmology and coordinated primary care referral systems.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize integrated diabetic eye care models that connect diabetes management, retinal screening, diagnosis, treatment, and follow-up within a single patient pathway. Investments should focus on interoperable imaging platforms, AI-supported triage, optical coherence tomography access, and referral systems that reduce time from abnormal screening to retina specialist evaluation. Product and service strategies should address real-world treatment burden by supporting longer-duration therapies, adherence programs, patient navigation, and flexible care settings.

Stakeholders should also strengthen evidence generation beyond controlled trials by tracking visual outcomes, injection frequency, adverse events, missed visits, and equity indicators in real-world populations. Partnerships with primary care providers, endocrinologists, optometrists, public health agencies, and community organizations can improve screening uptake among high-risk groups. In lower-resource settings, scalable approaches such as mobile retinal imaging, technician-led photography, cloud-based grading, and task-shifted screening can expand reach while preserving specialist capacity for treatment. Leaders should also prepare for stricter expectations around AI governance, data privacy, algorithmic fairness, and clinical accountability.

Research Methodology

This executive summary is developed using a structured secondary research approach grounded in verified clinical, regulatory, and public health sources. Evidence inputs include international diabetes and eye health publications, ophthalmology society guidelines, peer-reviewed clinical trial literature, health authority recommendations, disease burden reports, and documented screening program outcomes. The analysis emphasizes clinically validated treatment modalities for diabetic retinopathy and diabetic macular edema, including anti-VEGF therapy, corticosteroid-based approaches, laser photocoagulation, vitrectomy, retinal imaging, optical coherence tomography, teleophthalmology, and AI-enabled screening.

The methodology applies triangulation across epidemiological evidence, guideline consensus, care delivery patterns, technology adoption signals, and regional health system characteristics. Regional, group, and country insights are synthesized qualitatively to identify access dynamics, treatment infrastructure, screening maturity, and implementation barriers. The analysis intentionally excludes market sizing, market share, revenue estimation, and forecasting, focusing instead on data-backed clinical relevance, public health need, operational trends, and strategic implications for stakeholders in diabetes associated ophthalmic treatment.

Conclusion

Diabetes associated ophthalmic treatment is evolving into a prevention-led, digitally enabled, and multidisciplinary field. Rising diabetes prevalence, longer life expectancy, and persistent screening gaps are increasing the importance of early retinal assessment and timely intervention. Evidence-based therapies, especially anti-VEGF treatment for diabetic macular edema and proliferative diabetic retinopathy, have improved visual outcomes, while laser, corticosteroid, and surgical options remain essential for selected cases.

The next phase of progress will depend on integrating AI-supported screening, interoperable imaging, equitable access models, and adherence-focused care pathways. Regions and countries with organized screening programs, strong referral networks, and affordable specialist treatment are better positioned to reduce avoidable vision loss. For industry leaders, the strategic imperative is clear: build solutions that detect disease earlier, reduce treatment burden, support clinical decision-making, and deliver measurable improvements in patient outcomes across diverse health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Diabetes Associated Ophthalmic Treatment Market, by Product Type

  • 7.1. Introduction
  • 7.2. Drugs
    • 7.2.1. Biologics
    • 7.2.2. Small Molecules
  • 7.3. Devices
    • 7.3.1. Diagnostic Devices
    • 7.3.2. Surgical Devices
    • 7.3.3. Laser Systems

8. Diabetes Associated Ophthalmic Treatment Market, by Treatment Type

  • 8.1. Introduction
  • 8.2. Anti-VEGF
    • 8.2.1. Aflibercept
    • 8.2.2. Bevacizumab
    • 8.2.3. Brolucizumab
    • 8.2.4. Faricimab
    • 8.2.5. Ranibizumab
  • 8.3. Corticosteroids
    • 8.3.1. Dexamethasone Implant
    • 8.3.2. Fluocinolone Implant
    • 8.3.3. Triamcinolone
  • 8.4. Laser Therapy
    • 8.4.1. Focal/Grid Photocoagulation
    • 8.4.2. Panretinal Photocoagulation
  • 8.5. Surgical Intervention

9. Diabetes Associated Ophthalmic Treatment Market, by Route Of Administration

  • 9.1. Introduction
  • 9.2. Intravitreal Injection
    • 9.2.1. Prefilled Syringe
    • 9.2.2. Vial
  • 9.3. Systemic
    • 9.3.1. Intravenous
    • 9.3.2. Oral
  • 9.4. Topical
    • 9.4.1. Eye Drops
    • 9.4.2. Ointments

10. Diabetes Associated Ophthalmic Treatment Market, by Patient Type

  • 10.1. Introduction
  • 10.2. Type 1 Diabetes
  • 10.3. Type 2 Diabetes

11. Diabetes Associated Ophthalmic Treatment Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Hospitals
  • 11.4. Ophthalmology Clinics
  • 11.5. Retail Pharmacies

12. Diabetes Associated Ophthalmic Treatment Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Diabetes Associated Ophthalmic Treatment Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Diabetes Associated Ophthalmic Treatment Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adverum Biotechnologies, Inc.
  • 16.2. Alcon Vision LLC
  • 16.3. Alimera Sciences, Inc.
  • 16.4. Allergan PLC
  • 16.5. Amgen Inc
  • 16.6. Ampio Pharmaceuticals, Inc.
  • 16.7. ANI Pharmaceuticals, Inc.
  • 16.8. Apexian Pharmaceuticals, Inc.
  • 16.9. Bausch & Lomb Incorporated.
  • 16.10. Bayer AG
  • 16.11. Biocon Limited
  • 16.12. Biogen Inc.
  • 16.13. Carl Zeiss Meditec AG
  • 16.14. Eisai Co Ltd.
  • 16.15. F. Hoffmann-La Roche Ltd
  • 16.16. IRIDEX Corp.
  • 16.17. Johnson & Johnson Services, Inc.
  • 16.18. Kalvista Pharmaceuticals Ltd.
  • 16.19. Kodiak Sciences Inc.
  • 16.20. Kubota Vision Inc.
  • 16.21. Lumenis
  • 16.22. Novartis AG
  • 16.23. Ocuphire Pharma, Inc.
  • 16.24. Pfizer, Inc.
  • 16.25. Regeneron Pharmaceuticals Inc.
  • 16.26. Samsung Biologics Co., Ltd.
  • 16.27. Sandoz Group AG
  • 16.28. Santen Pharmaceutical Co. Ltd.
  • 16.29. Topcon Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL SMALL MOLECULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL SMALL MOLECULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL SMALL MOLECULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIAGNOSTIC DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL SURGICAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL SURGICAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL SURGICAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LASER SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LASER SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LASER SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-VEGF MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-VEGF MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-VEGF MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AFLIBERCEPT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AFLIBERCEPT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AFLIBERCEPT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BEVACIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BEVACIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BEVACIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BROLUCIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BROLUCIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BROLUCIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FARICIMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL FARICIMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL FARICIMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL RANIBIZUMAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL RANIBIZUMAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL RANIBIZUMAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CORTICOSTEROIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DEXAMETHASONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL FLUOCINOLONE IMPLANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL FLUOCINOLONE IMPLANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL FLUOCINOLONE IMPLANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TRIAMCINOLONE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TRIAMCINOLONE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TRIAMCINOLONE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LASER THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LASER THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LASER THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL FOCAL/GRID PHOTOCOAGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL FOCAL/GRID PHOTOCOAGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL FOCAL/GRID PHOTOCOAGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PANRETINAL PHOTOCOAGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PANRETINAL PHOTOCOAGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PANRETINAL PHOTOCOAGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL SURGICAL INTERVENTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL SURGICAL INTERVENTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SURGICAL INTERVENTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INTRAVITREAL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PREFILLED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL VIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL VIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL VIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL SYSTEMIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL SYSTEMIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL SYSTEMIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INTRAVENOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INTRAVENOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INTRAVENOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ORAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ORAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TOPICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TOPICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TOPICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EYE DROPS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EYE DROPS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EYE DROPS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OINTMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OINTMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OINTMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL AMBULATORY SURGICAL CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OPHTHALMOLOGY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. MIDDLE EAST DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 202. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 203. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 205. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 208. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 209. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 212. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 213. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 214. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. NATO DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 217. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 219. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 222. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 223. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 226. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 227. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 228. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 259. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 261. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 262. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 272. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 274. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 275. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 276. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 278. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 279. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 280. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 281. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 282. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 283. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 284. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. GCC DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 286. GLOBAL DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY CORTICOSTEROIDS, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY LASER THERAPY, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY SYSTEMIC, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 318. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 319. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. JAPAN DIABETES ASSOCIATED OPHTHALMIC TREATMENT MARKET SIZE, BY ANTI-VEGF, 2018-2032 (USD MILLION)

TABLE